Unfortunately, cancer is a leading cause of death in the United States. Each and every year, employers, insurance companies, taxpayer-funded programs, and patients and their families spend more than 150 billion dollars on cancer-related health care.¹ Yet despite the availability of more advanced screening methods and treatments, we are still fighting a losing battle. This is particularly true for lung cancer, for which survival rates have not significantly improved in more than 50 years.²

Oncocyte is a molecular diagnostics company with a mission to provide actionable answers to physicians and patients at critical decision points across the cancer care continuum. Our goal is to provide tests and solutions that may help diagnosis and treatment, leading to improved patient outcomes and reducing the overall cost of care.

Oncocyte’s leadership team has extensive experience in molecular diagnostics and is dedicated to advancing the continuum of care in lung cancer.